Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists

Thrombosis and Haemostasis

Volumn 116, Issue 1, 2016, Pages 155-161

  Brekelmans, Marjolein P A ^a   Bleker, Suzanne M ^a   Bauersachs, Rupert ^b   Boda, Zoltan ^c   Büller, Harry R ^a   Choi, Youngsook ^d   Gallus, Alex ^e   Grosso, Michael A ^d   Middeldorp, Saskia ^a   Oh, Doyeun ^f   Raskob, Gary ^g   Schwocho, Lee ^d   Cohen, Alexander T ^h  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b KLINIKUM DARMSTADT   (Germany)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d DAIICHI SANKYO INC   (United States)

^e FLINDERS UNIVERSITY   (Australia)

^f CHA University   (South Korea)

^g UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^h KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anticoagulants; Coumarins; Edoxaban; Haemorrhage; Venous thromboembolism

Indexed keywords

ANTIVITAMIN K; EDOXABAN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; VITAMIN K GROUP; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; DOUBLE BLIND PROCEDURE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DOUBLE-BLIND METHOD; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; PYRIDINES; RISK FACTORS; THIAZOLES; VENOUS THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84977574459     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-11-0892     Document Type: Article

References (23)

1. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 257S-298S.
2. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
3. Hylek EM. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. J Thromb Thrombolysis 2013; 35: 333-335.
4. Leendertse AJ, Egberts AC, Stoker LJ, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168: 1890-1896.
5. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
6. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
7. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
8. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
9. Büller HR, Décousus H, Grosso M, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
10. van der Hulle T, Kooiman J, den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and metaanalysis. J Thromb Haemost 2014; 12: 320-328.
11. van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute symptomatic venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968-1975.
12. Kaatz S, Crowther M. Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis 2013; 36: 195-202.
13. Levi MM, Eerenberg E, Lowenberg E, et al. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010; 68: 68-76.
14. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
15. Eerenberg ES, Middeldorp S, Levi M, et al. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. J Thromb Haemost 2015; 13: 1590-1596.
16. Raskob G, Buller H, Prins M, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost 2013; 11: 1287-1294.
17. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e44S-e88S.
18. Van Es J, Eerenberg ES, Kamphuisen PW, et al. How to prevent, treat, and overcome current clinical challenges of VTE. J Thromb Haemost 2011; 9 (Suppl 1): 265-274.
19. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157-164.
20. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
21. Berger R, Salhanick SD, Chase M, et al. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. Ann Emerg Med 2013; 61: 475-479.
22. Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83: 137-143.
23. Johansen M, Wikkelso A, Lunde J, et al. Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients. Cochrane Database System Rev 2015; 7: Cd010555.